Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-681323 in rheumatoid arthritis: 28-day randomized placebo-controlled trial
2005-002219-26Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SB-681323 with Placebo (2 arms). Primary endpoints: Serum C-reactive protein (CRP) level at day 28 and Safety and tolerability. Started Jul 2005; status: completed.
02
Drugs
dilmapimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-002219-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002219-26.